Johnson & Johnson MedTech announced positive three-month results from a study evaluating its investigational Omnypulse platform.

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

Often seen as an option of last resort for ventricular tachycardia, new research suggests catheter ablation could have a ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an ...

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...

About VIVO Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Medical device company Boston Scientific (NYSE:BSX) announced in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...